MPEP 2412.03(e)
"Modified Nucleotide"

Ninth Edition of the MPEP, Revision 07.2022, Last Revised in February 2023

Previous: §2412.03(d) | Next: §2412.04

2412.03(e)    "Modified Nucleotide" [R-07.2022]

[Editor Note: This section is applicable to all applications filed on or after July 1, 2022, having disclosures of nucleotide and/or amino acid sequences as defined in 37 CFR 1.831(b).]

37 C.F.R. 1.831  Requirements for patent applications filed on or after July 1, 2022, having nucleotide and/or amino acid sequence disclosures.

  • *****

  • (i) "Modified nucleotide" includes any nucleotide as described in paragraph 3(f) of WIPO Standard ST.26.
  • *****

WIPO Standard ST.26, paragraph 3(f), identifies that a "modified nucleotide" means any "nucleotide" as explained in MPEP § 2412.03(d) other than deoxyadenosine 3’-monophosphate, deoxyguanosine 3’-monophosphate, deoxycytidine 3’-monophosphate, deoxythymidine 3’-monophosphate, adenosine 3’-monophosphate, guanosine 3’-monophosphate, cytidine 3’-monophosphate, or uridine 3’-monophosphate.